These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 30074496)

  • 1. Advances in management of Guillain-Barré syndrome.
    Doets AY; Jacobs BC; van Doorn PA
    Curr Opin Neurol; 2018 Oct; 31(5):541-550. PubMed ID: 30074496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosis, treatment and prognosis of Guillain-Barré syndrome (GBS).
    van Doorn PA
    Presse Med; 2013 Jun; 42(6 Pt 2):e193-201. PubMed ID: 23628447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain-Barré syndrome.
    van Doorn PA; Van den Bergh PYK; Hadden RDM; Avau B; Vankrunkelsven P; Attarian S; Blomkwist-Markens PH; Cornblath DR; Goedee HS; Harbo T; Jacobs BC; Kusunoki S; Lehmann HC; Lewis RA; Lunn MP; Nobile-Orazio E; Querol L; Rajabally YA; Umapathi T; Topaloglu HA; Willison HJ
    Eur J Neurol; 2023 Dec; 30(12):3646-3674. PubMed ID: 37814552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain-Barré syndrome.
    van Doorn PA; Van den Bergh PYK; Hadden RDM; Avau B; Vankrunkelsven P; Attarian S; Blomkwist-Markens PH; Cornblath DR; Goedee HS; Harbo T; Jacobs BC; Kusunoki S; Lehmann HC; Lewis RA; Lunn MP; Nobile-Orazio E; Querol L; Rajabally YA; Umapathi T; Topaloglu HA; Willison HJ
    J Peripher Nerv Syst; 2023 Dec; 28(4):535-563. PubMed ID: 37814551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IVIG treatment and prognosis in Guillain-Barré syndrome.
    van Doorn PA; Kuitwaard K; Walgaard C; van Koningsveld R; Ruts L; Jacobs BC
    J Clin Immunol; 2010 May; 30 Suppl 1(Suppl 1):S74-8. PubMed ID: 20396937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome.
    van Doorn PA; Ruts L; Jacobs BC
    Lancet Neurol; 2008 Oct; 7(10):939-50. PubMed ID: 18848313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guillain-Barré syndrome: clinical profile and management.
    Sudulagunta SR; Sodalagunta MB; Sepehrar M; Khorram H; Bangalore Raja SK; Kothandapani S; Noroozpour Z; Aheta Sham M; Prasad N; Sunny SP; Mohammed MD; Gangadharappa R; Nidsale Sudarshan R
    Ger Med Sci; 2015; 13():Doc16. PubMed ID: 26421004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second IVIg course in Guillain-Barré syndrome patients with poor prognosis (SID-GBS trial): Protocol for a double-blind randomized, placebo-controlled clinical trial.
    Walgaard C; Jacobs BC; Lingsma HF; Steyerberg EW; Cornblath DR; van Doorn PA;
    J Peripher Nerv Syst; 2018 Dec; 23(4):210-215. PubMed ID: 30151941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Novel Therapeutic Interventions in Guillain-Barré Syndrome: Review and Future Perspective].
    Misawa S
    Brain Nerve; 2015 Nov; 67(11):1421-8. PubMed ID: 26560957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prognostic factors in Guillain-Barré syndrome].
    Kaida K
    Rinsho Shinkeigaku; 2013; 53(11):1315-8. PubMed ID: 24291972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guillain-Barré syndrome: epidemiology, pathophysiology and management.
    Kuwabara S
    Drugs; 2004; 64(6):597-610. PubMed ID: 15018590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatments and outcome predictors in Guillain-Barré syndrome].
    Uchibori A; Chiba A
    Nihon Rinsho; 2013 May; 71(5):845-9. PubMed ID: 23777092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of Guillain-Barré Syndrome].
    Nomura K
    Brain Nerve; 2015 Nov; 67(11):1397-410. PubMed ID: 26560955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guillain-Barré syndrome (GBS).
    Pithadia AB; Kakadia N
    Pharmacol Rep; 2010; 62(2):220-32. PubMed ID: 20508277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prognostic Factors in Guillain-Barré Syndrome].
    Kaida K
    Brain Nerve; 2015 Nov; 67(11):1411-9. PubMed ID: 26560956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy of Guillain-Barré syndrome.
    Liu S; Dong C; Ubogu EE
    Hum Vaccin Immunother; 2018; 14(11):2568-2579. PubMed ID: 29953326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress in Guillain-Barré syndrome immunotherapy-A narrative review of new strategies in recent years.
    Yao J; Zhou R; Liu Y; Lu Z
    Hum Vaccin Immunother; 2023 Aug; 19(2):2215153. PubMed ID: 37278272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Therapeutic Plasma Exchange in Guillain-Barre Syndrome after Allogeneic Hematopoietic Stem Cell Transplant: Report of Two Cases.
    Cekdemir D; Ozkan HA; Korkmaz F; Ozgurel Y; Kural S; Tiryaki N; Gulbas Z
    Clin Lab; 2021 Mar; 67(3):. PubMed ID: 33739028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in the management of Guillain-Barré syndrome.
    Green DM
    Curr Neurol Neurosci Rep; 2002 Nov; 2(6):541-8. PubMed ID: 12359110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment dilemmas in Guillain-Barré syndrome.
    Verboon C; van Doorn PA; Jacobs BC
    J Neurol Neurosurg Psychiatry; 2017 Apr; 88(4):346-352. PubMed ID: 27837102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.